12:00 AM
 | 
Jan 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cladribine tablets: Additional Phase III data

Additional data from the double-blind, international Phase III CLARITY trial in 1,326 patients with relapsing-remitting MS showed that 3.5 and 5.25 mg/kg oral cladribine significantly increased relapse-free rates vs. placebo (79.7% and 78.9% vs. 60.9%, p<0.001 for both), lowered the risk of 3-month sustained progression of disability vs. placebo (p=0.02 and p=0.03, respectively)...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >